Case Report: Personalized treatment in stage IV breast cancer using the patient-derived organoids
Breast cancer, especially stage IV breast cancer, is highly heterogeneous at morphological and molecular levels. Recently, the role of patient-derived organoids (PDOs) has become increasingly prominent in cancer research and personalized medicine. They are not only used to predict the clinical respo...
Saved in:
| Main Authors: | Wu Ying, Hao Pi, Xiaowu He, Yuan Sheng |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1629690/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Partial Response Achieved in a Case of Metastatic Triple-Negative Breast Cancer Based on the Patient-Derived Tumor Organoids
by: Liu Y, et al.
Published: (2025-07-01) -
Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis
by: Yaping Zhang, et al.
Published: (2025-06-01) -
Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis
by: Maria Inez Dacoregio, et al.
Published: (2025-02-01) -
Targeting Refractory Triple-Negative Breast Cancer with Sacituzumab Govitecan: A New Era in Precision Medicine
by: Saif Khan, et al.
Published: (2024-12-01) -
UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
by: Megan H. Wong, et al.
Published: (2024-08-01)